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Abstract: Metabotropic glutamate receptors (mGluRs) are important drug targets because of their 
involvement in several neurological diseases. Among mGluRs, mGlu5 is a particularly high-profile target because its positive 
or negative allosteric modulation can potentially treat schizophrenia or anxiety and chronic pain, respectively. Here, we 
computationally and experimentally probe the functional binding of a novel photoswitchable mGlu5 NAM, termed 
alloswitch-1, which loses its NAM functionality under violet light. We show alloswitch-1 binds deep in the allosteric 
pocket in a similar fashion to mavoglurant, the co-crystallized NAM in the mGlu5 transmembrane domain crystal structure. 
Alloswitch-1, like NAM 2-Methyl-6-(phenylethynyl)pyridine (MPEP), is significantly affected by P655M mutation deep in the 
allosteric pocket, eradicating its functionality. In MD simulations, we show alloswitch-1 and MPEP stabilize the co-crystallized 
water molecule located at the bottom of the allosteric site that is seemingly characteristic of the inactive receptor state. 
Furthermore, both NAMs form H-bonds with S809 on helix 7, which may constitute an important stabilizing interaction for 
NAM-induced mGlu5 inactivation. Alloswitch-1, through isomerization of its amide group from trans to cis is able to form an 
additional interaction with N747 on helix 5. This may be an important interaction for amide-containing mGlu5 NAMs, helping to 
stabilize their binding in a potentially unusual cis-amide state. Simulated conformational switching of alloswitch-1 in silico 
suggests photoisomerization of its azo group from trans to cis may be possible within the allosteric pocket. However, 
photoexcited alloswitch-1 binds in an unstable fashion, breaking H-bonds with the protein and destabilizing the co-crystallized 
water molecule. This suggests photoswitching may have destabilizing effects on mGlu5 binding and functionality.	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INTRODUCTION	  
 As the most significant excitatory neurotransmitter in the 
CNS, glutamate is involved in a whole host of diverse 
neurological disorders such as chronic pain, epilepsy and 
Alzheimer’s [1-3]. It operates through two distinct kinds of 
transmembrane receptors: ionotropic cation channels for fast 
neuronal ionic transmission [4] and metabotropic glutamate 
(mGlu) G protein-coupled receptors (GPCRs) for sustained 
but slower modulation of neuronal synaptic activity [5-7]. 
The mGlu receptor (mGluR) family contains eight member 
subtypes each consisting of disulphide-linked dimers [7, 8]. 
Each protomer contains an extracellular Venus flytrap (VFT) 
domain where the orthosteric (glutamate) binding-site is 
located and a heptahelical transmembrane (TM) domain 
where allosteric binding-sites are found. Of all mGluRs,  
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mGlu5 is a particularly attractive target for pharmacological 
modulation because its stimulation can potentially be a 
therapy for schizophrenia [9] whilst its inhibition can 
potentially treat anxiety [10], depression [11] and pain [12-
14]. Despite different mGluR VFT domains having been 
crystallized since 2000 [15-17], the targeting of the orthosteric 
site of mGluRs with agonists or antagonists that compete 
with glutamate has yielded mixed results. This is partly 
because mGluRs contain very similar VFT domains making 
subtype selectivity a problem [18]. This has spurned the 
development of mGluR positive and negative allosteric 
modulators (PAMs and NAMs, respectively), which potentially 
offer better selectivity by binding in the TM domain where 
structural differences are more apparent amongst family 
members [19, 20]. As a further benefit, there is a reduced 
risk of mGluR over-sensitization as strict allosteric modulators 
(those with no intrinsic agonist activity) only modulate natural 
responses to glutamate and do not activate the receptor 
themselves [18]. This means spatial and temporal effects of 
glutamate can be maintained, which is a therapeutically 
desirable feature. However, until very recently, no mGluR 
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TM domain (or even close homologue) had been crystallized, 
making high-level exploration of the allosteric site of mGlu5 
difficult despite various homology models built on distantly 
related GPCRs [21-23]. However, with the release of the 
crystal structure of the TM domain of mGlu5 in an inactive 
state with bound NAM mavoglurant in 2014 [24], as well as 
the TM domain of mGlu1 [25], much more accurate studies 
of NAM and PAM binding to mGlu5 have become possible. 	  
 Here we take advantage of the mGlu5 TM domain crystal 
structure (henceforth referred to as mGlu5) to investigate, in 
silico and in vitro, mGlu5 NAM binding, functionality and 
potential mechanisms of receptor recognition with regards to 
negative allosteric action. For this we compare two mGlu5 
NAMs with respect to co-crystallized mavoglurant [24]:  
the well-characterized 2-Methyl-6-(phenylethynyl)pyridine 
(MPEP) [26-28] and a novel photoswitchable compound 
called alloswitch-1, which has recently been developed [29] 
(see Fig. 1). Alloswitch-1 is similar to other mGlu5 NAMs in 
that it contains three aromatic rings connected by two spacer 
groups [21, 23, 30]. The first of these spacers is a rigid trans-
azo group, which is similar in length to a rigid ethynyl group, 
previously identified as an important structural feature of 
several mGlu5 NAMs [31, 30] and also present in mavoglurant 
[24]. However, the azo group has the added capability of 
photoswitching under violet light into a cis-azo configuration 
and back to a normal trans-azo state under green light or 
thermally in the dark [29] (Fig. 1). Experiments have shown 
that alloswitch-1 acts as a potent NAM in dark or under 
green light but loses its NAM potency under violet light 
when photoisomerized [29]. It is currently unknown whether 
this photo-induced loss of NAM functionality is due to a loss 
of ligand binding to mGlu5 or a more subtle effect such as a 
change in binding mode or a ligand-induced effect on 
receptor conformation. Indeed, it is also unknown whether 
photoswitching of alloswitch-1 can occur inside the 
allosteric site of mGlu5 whilst the ligand is bound or whether 
it only occurs in the solvent in an unbound state. 
 Here, we attempt to answer some of these questions from a 
theoretical point of view by employing computational docking 
and molecular dynamics (MD) simulations. Furthermore, by 
combining experimental and computational approaches, we 
seek to establish the functional NAM binding-mode of the 
trans-azo conformation of alloswitch-1, as well as that of 
MPEP, and therefore by extension other similar mGlu5 
NAMs. In particular, the second spacer group of alloswitch-1 
consists of an amide, which is another common constituent of 
many mGlu5 NAMs [30] but its functional significance is not 
quite understood. We explore some theoretical possibilities 
why the conformational state of this amide group may be 
significant for the NAM functionality of alloswitch-1 and 
potentially other mGlu5 NAMs. 
RESULTS AND DISCUSSION	  
 In order to investigate NAM functionality in mGlu5 in 
silico, the missing second intracellular and extracellular 
loops (ICL2 and ECL2) of the mGlu5 crystal structure (PDB 
id 4OO9) were constructed with MODELLER [32] and 
unnatural amino-acids in the TM domain converted back to 
wild-type with CHIMERA [33] (see Methods). As a control 
for validating a reliable NAM docking protocol for wt 
mGlu5, we redocked the co-crystallized NAM mavoglurant 
back into the empty allosteric binding pocket of the TM 
domain using Autodock-4.2 [34], seeking to reproduce the 
crystal binding pose. Fig. 2 shows the top-ranked docking 
solution of mavoglurant in wt mGlu5, with an RMSD of 0.2 
Å compared to the crystal state. This best-ranked solution re-
establishes all protein-ligand H-bonds and important 
interactions observed in the original crystal structure. In 
particular, the carbon-carbon triple bond of mavoglurant 
traverses a narrow region in the pocket between P655 on 
TM3 and S809 on TM7, enabling the methylated aromatic 
ring of mavoglurant to occupy a larger space at the bottom  
of the allosteric pocket, located between G624 on TM2, 
Y659 on TM3, A810 on TM7, and a co-crystallized water 
molecule (which forms a three-way H-bonding network with 
Y659, T781 and S809). We took this result as a validation of 
our docking protocol, which we then extended to other 
NAMs. 
 MPEP is often considered a standard mGlu5 NAM with 
which other molecules are compared as it has been well 
characterized experimentally with important receptor 
residues identified for binding e.g. W785, F788, S809 and 
A810 amongst others [21, 28, 35, 36]. Interestingly, like 
mavoglurant, MPEP contains a methylated aromatic ring. 
We therefore docked MPEP into mGlu5 with Autodock-4.2 
to compare its binding mode with that of mavoglurant. As 
anticipated, MPEP docks in a very similar binding mode to 
mavoglurant (in all reported top 10 docking solutions) with 
its methylated pyridine ring occupying the same position as 
methylated benzene of mavoglurant (see Fig. 3A for the top-
ranked solution). This is in agreement with another recent 
study where MPEP was docked into the crystal structure of 
mGlu5 [37]. Furthermore, like mavoglurant, S809 on TM7 is 
observed to make an H-bond with MPEP. However, unlike 
mavoglurant, S809 acts as a proton donor to the nucleophilic 
nitrogen on the pyrindine ring of MPEP. This H-bonding 
does not affect the rotameric position of the sidechain, which 
remains unchanged with respect to the crystal structure, but 
 
Fig. (1). The chemical structure of alloswitch-1 and conversion to cis-azo during photoswitching with violet light (380-390 nm) and back to 
ground trans-azo state by either relaxation in dark or photoinduced with green light (490-500 nm). 
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involves a rotation of its hydroxyl group. Other differences 
compared to mavoglurant include a lack of protein-ligand H-
bonds with respect to N747 on TM5 and S805 on TM7. 
These “missing” interactions are a result of MPEP being 
shorter in length and not containing some of the chemical 
groups possessed by mavoglurant. The rest of the receptor, 
including the co-crystallized water molecule between TM3, 
TM6 and TM7 (identified by Marshall et al. [24]) remains 
unchanged with respect to the original crystal structure 
(except mutated residues reverted back to wt). 
 In order to validate the predicted binding-mode of MPEP, 
we pursued two different exploratory lines: (i) experimentally 
 
Fig. (2). The best-ranked docking solution of mavoglurant (in blue) in the complete wt structure of mGlu5 (in beige). All protein-ligand H-
bonds originally identified in the crystal structure (PDB id: 4OO9) were reformed during docking (orange lines, involving residues N747, 
S805, S809). For visualisation purposes, the backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are 
included (in the foreground), with the latter making an H-bond with a co-crystallized water molecule. Regarding helix position, TM5 is 
foreground left, TM7 is foreground right. In the background, TM4 is left, TM3 is central and TM2 is right. 
 
 
Fig. (3). A) The best-ranked docking solution of MPEP (in blue) in the complete wt structure of mGlu5 (in beige). B) After 130 ns of MD 
simulation. H-bonds are shown as orange lines. A protein-ligand H-bond between MPEP and S809 is formed. For visualisation purposes, the 
backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are included (in the foreground). Regarding 
helix position, TM5 is foreground left, TM7 is foreground right. In the background, TM3 is centre-left and TM2 is centre-right. 
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by making mutations at the top and bottom of the allosteric 
pocket (see SI Fig. 1) and studying their effect on MPEP 
functionality, and (ii) computationally with an MD 
simulation, incorporating wt mGlu5 with bound MPEP in an 
explicit water/lipid-membrane environment for studying 
receptor-ligand behaviour and comparison with previously 
reported mutational data [28, 38]. As previously mentioned, 
the carbon-carbon triple bond of MPEP is predicted to 
traverse a narrow region at the bottom of the allosteric 
pocket between P655 and S809, like mavoglurant. As such, 
mutating P655 into a bulkier residue was anticipated to 
adversely affect MPEP binding and disrupt NAM 
functionality in mGlu5. This residue has previously been 
mutated to serine, reducing mGlu5 affinty for MPEP but not 
abolishing its binding or functionality [38]. It was therefore 
decided to mutate this residue to methionine as this is the 
equivalent residue in mGlu4, which would likely not 
compromise mGlu5 activity but be bulky enough to 
potentially abolish MPEP functionality (assuming the 
prediction of MPEP binding pose is correct). This hypothesis 
was tested by making the P655M mutation and determining 
antagonist activity of MPEP on the effect of orthosteric 
agonist quisqualate (see Methods). As predicted, the P655M 
mutation significantly affects MPEP functionality, effectively 
abolishing its NAM capability whilst also preserving normal 
receptor activity in response to agonist (see Fig. 4, SI Table 1). 
Presumably this mutation prevents MPEP from binding in its 
preferred orientation. In agreement with this hypothesis, re-
docking MPEP and mavoglurant into a model of the P655M 
mutant is unable to replicate either of the predicted binding 
modes observed in the wt as methionine fills the narrow 
space where they previously bound (data not shown). These 
results support the notion that MPEP, like mavoglurant, 
binds in the lower cavity of the allosteric pocket. An 
additional Q647A mutation was made at the top of the 
allosteric site in mGlu5. The rationale for making this 
mutation is that the equivalent residue in the mGlu1 crystal 
structure is in close proximity to NAM FITM, which has a 
higher laying binding pose at the top of the allosteric pocket 
[25]. However, Q647 lies above mavoglurant in the mGlu5 
crystal structure and does not interact with the ligand (SI Fig. 1). 
As MPEP is predicted to follow the same binding pattern as 
mavoglurant, mutation of Q647 was not anticipated to affect 
MPEP activity. As expected, this mutation does not affect 
MPEP and does not affect normal agonist-induced activation 
of the receptor (Fig. 4, SI Table 1). 
 
Fig. (4). Pharmacological validation of MPEP and alloswitch-1 binding mode. Concentration-response curves of quisqualate (Red), MPEP 
(Blue) and alloswitch-1 (Green) in (A) wild-type rat mGlu5 receptors, (B) Q646A (equivalent to Q647A in human mGlu5) or (C) P654M 
(equivalent to P655M in human mGlu5) mutated rat mGlu5 receptors. MPEP and alloswitch-1 activities were evaluated in the presence of 30 nM 
of quisqualate. HEK293 cells were transiently transfected with the mGlu5 receptor constructs. Receptor activation following stimulation by 
different concentrations of ligands was determined by IP1 production (see methods). Each data point corresponds to means ± SEM of at least 3 
experiments performed in triplicate. 
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 In an MD simulation of docked MPEP in wt mGlu5, the 
ligand remains bound to the receptor in a stable orientation 
with little deviation over the course of 130 ns (see Fig. 3B 
and SI Fig. 2) with the final RMSD of MPEP pyridine ring, 
0.5 Å, and the receptor, 2.0 Å. Furthermore, although the 
predicted H-bond between S809 and MPEP is temporarily 
broken mid-simulation as the rotameric state of S809 flips 
(forming an H-bond with the mainchain oxygen atom of 
S805), it is later recovered and maintained (SI Fig. 3). This 
suggests an S809-MPEP H-bond contributes to NAM 
functionality (as supported by previous S809 mutations, 
which reduce MPEP potency [28]) and also perhaps 
indicates that S809 can operate as an allosteric toggle switch. 
In addition, other features of interest in the mGlu5-MPEP 
simulation include (i) stabilization of the co-crystallized 
water molecule at the bottom of the allosteric pocket [24], 
which remains unchanged with respect to the receptor, (ii) 
introduction of a second water molecule into the allosteric 
pocket, which H-bonds between S805 and S809, in a similar 
manner to the hydroxyl group of mavoglurant (Fig. 2 and 
3B), (iii) a partial inward movement of W785 sidechain in 
the allosteric pocket with respect to the outward orientation 
seen in the mavoglurant-bound crystal structure [24] (Fig. 
3B), and (iv) an adjustment in the plane of MPEP that 
optimises hydrophobic interactions with L744 (TM5), W785, 
F788 (TM6) and M802 (TM7, see SI Fig. 4). Two of these 
residues in particular, W785 and F788, have been found to 
reduce the potency of MPEP when mutated to alanine [28]. 
Collectively, these features (observations from simulation 
and reported mutational data) point to a validation of the 
MPEP docking pose at the bottom of the allosteric pocket. 
 We next proceeded to dock the active isomer of 
alloswitch-1 into mGlu5 in its original crystal structure 
conformation. Alloswitch-1 is an unusual molecule because 
it contains two spacer groups between three aromatic rings 
that can theoretically display either cis or trans dispositions 
(Fig. 1). One of these is a rigid azo group which normally 
resides in a lower-energy trans-position but can isomerize 
into a higher-energy cis-state when violet light is applied 
(forming a non-active isomer) [29]. The other is a partially 
flexible amide group, which can be promoted from low-
energy trans-states to higher-energy cis-states when 
conditions are favourable, such as those seen in protein 
folding (predominantly but not exclusively involving 
prolines) [39] or organic molecules with stabilizing intra-
molecular interactions e.g. pentafluorophenyl-containing 
ligands [40]. Accordingly, but somewhat unexpectedly, when 
alloswitch-1 in the trans-azo configuration, corresponding to 
the active form in the dark, is docked into the original crystal 
structure of mGlu5 with Autodock-4.2 (see Methods), the 
ligand adopts a cis-amide state in 9 out of 10 docking 
solutions. As might be expected, in 7 of the best docking 
solutions (SI Fig. 5), including the top-ranked solution  
(Fig. 5A), the orientation of the pyridine ring of alloswitch-1 
adopts the same orientation as the pyridine ring of MPEP, 
binding deep in the allosteric site. Furthermore, the azo-
group adopts the same orientation as the carbon triple bond 
in MPEP (and mavoglurant), traversing the narrow gap 
between P655 on TM3 and S809 on TM7. This binding 
mode appears to be confirmed by experiment which shows 
that alloswitch-1, like MPEP, is signficantly affected by the 
P655M mutation (Fig. 4, SI Table 1). More unusually 
however, in the higher region of the allosteric pocket, the 
amide bond prefers a cis conformation facilitating a ligand 
“L” shape and maximizing favourable interactions with the 
receptor (Fig. 5A). In this way, interactions with N747 on 
 
Fig. (5). A) The best-ranked docking solution of the active isomer of alloswitch-1 (in green) in the complete wt structure of mGlu5 (in beige) 
where the ligand adopts a cis-amide conformation. B) After 100 ns of MD simulation “in the dark”. H-bonds are shown as orange lines and 
halogen interactions as dotted black lines. A protein-ligand H-bond between alloswitch-1 and S809 is formed during MD. For visualisation 
purposes, the backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are included (in the foreground). 
Regarding helix position, TM5 is foreground left, TM7 is foreground right. In the background, TM3 is centre-left and TM2 is centre-right. 
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TM5 can be formed (N747 has been shown to be important 
for the affinity of amide-containing NAMs, of which 
alloswitch-1 is an example, but not other non-amide NAMs 
[41]) as well as avoiding unfavourable interactions with 
F788 on TM6 (SI Fig. 6). As this result is replicated in the 
majority of docking solutions, it is unlikely to be an artefact. 
Although it is possible to find a much lower-ranked docking 
solution where alloswitch-1 adopts a more conventional 
trans-amide conformation, this has the consequence of 
forcing the ligand much deeper into the allosteric pocket of 
mGlu5 than that explored by mavoglurant or MPEP, creating 
unfavourable interactions with Y659 and the co-crystallized 
water molecule (SI Fig. 5). This would seem inconsistent 
with the crystal structure binding-mode of mGlu5 NAMs as 
well as from a purely energetic point of view. These results 
suggest a ligand cis-amide is the more likely conformation 
when the receptor is in its crystal state. 
 In a similar manner to that performed with MPEP, the 
top-ranked docking solution of alloswitch-1 (with cis-amide) 
was subjected to an MD simulation over 100 ns. During the 
simulation, the ligand remains stably bound to mGlu5 in its 
cis-amide conformation (final RMSD of ligand pyridine ring 
compared to docking: 1.0 Å, and receptor RMSD: 2.1 Å, SI 
Fig. 7). In addition, the methoxy group of alloswitch-1 binds 
between L744 on TM5 and W785, F788 on TM6. This 
maintains W785 in an outward orientation as seen in the 
mavoglurant-bound crystal structure and also means the 
ligand methoxy group rests partially out of plane with 
respect to the rest of the molecule (SI Fig. 6). Furthermore, 
the co-crystallized water molecule at the bottom of the 
allosteric pocket [24] remains stable over 100 ns (as in the 
MPEP-containing MD simulation), however a second water 
molecule enters the allosteric pocket, binding between 
alloswitch-1, Y659 (TM3) and W785 (TM6). Perhaps most 
interestingly of all, and despite not being directly predicted 
by docking, S809 forms a stable H-bond with the pyridine 
ring of alloswitch-1. This occurs early in the MD simulation 
as the ligand pyridine ring quickly but subtlely shifts its 
position in the allosteric pocket (Fig. 5B, SI Fig. 8). This 
binding-mode closely mimics the predicted binding-mode of 
MPEP, where an interaction between S809 and ligand 
pyridine ring has previously been suggested as functionally 
relevant [28]. An optimized conformation of the active 
(trans-azo) isomer of alloswitch-1 with cis-amide was also 
separately generated by density functional theory (DFT) 
using Gaussian [42] (independently of the receptor, see 
Methods and SI Fig. 9). This was compared with the top-
ranked docking solution of alloswitch-1 in mGlu5 before and 
after 100 ns of MD. The top docking solution of alloswitch-1 
contains an amide dihedral angle of -8.7° and after MD, this 
shifts to 4.2°. This is in close agreement with the lowest-
energy conformation generated by DFT, which contains a 
dihedral angle of 6.8° (SI Fig. 9). This suggests alloswitch-1 
is able to adopt a near-optimal cis conformation within the 
allosteric pocket. 	  
 As the proposed binding-mode of alloswitch-1 with a cis-
amide is an unusual feature and as GPCRs are dynamic 
molecules with potentially different signalling conformational 
states [43], an alternative conformation of mGlu5 was 
derived from the original crystal structure in order to explore 
other feasible binding modes of alloswitch-1. This alternative 
receptor conformation was found with ROSETTA 
conformational sampling (minus mavoglurant, see Methods) 
and deemed to be still in an inactive receptor state. Although 
similar to the crystal structure, it has a wider allosteric 
pocket (SI Fig. 10) created by different side-chain packing 
between TM6 and TM7 (Fig. 6). In particular, this involves 
an outward flipping of F788 sidechain on TM6 and an 
inward motion of adjacent S805 sidechain on TM7. 
However, this alternative conformation still preserves the co-
crystallized water molecule between Y659, T781 and S809 
in the allosteric pocket and other intracellular interactions 
observed in the original mGlu5 crystal structure [24]. 
Alloswitch-1 was re-docked into this alternative mGlu5 
conformation with all top 10 docking solutions identifying a 
ligand conformation containing a trans-azo and trans-amide 
with a high degree of structural overlap (max RMSD range 
of 2.3 Å; SI Fig. 11). In the top-ranked solution (Fig. 7A), 
the ligand pyridine ring occupies the bottom of the allosteric 
pocket as seen previously in the cis-amide conformation, 
although no specific protein-ligand H-bonds are predicted, 
nor interaction with N747 on TM5 (predicted docking score 
remains less than the predicted cis-amide conformation; SI 
Table 2). In an MD simulation of 100 ns, the trans-amide 
conformation of alloswitch-1 binds in a stable manner with 
the bound co-crystal water molecule [24] stabilized as in 
previous simulations (final RMSD of ligand pyridine ring 
compared to docking: 1.3 Å, and receptor RMSD: 2.2 Å; SI 
Fig. 12). However, three additional water molecules enter the 
allosteric pocket as its volume is higher in this conformation 
than in the original crystal structure (250 Å3 compared to 
213 Å3 as calculated with POVME [44]). In addition, the 
directionality of the water-mediated H-bonding between 
TM3 and TM6 is altered (Fig. 7B) as Y659 (TM3) and T781 
(TM6) become connected by two water molecules rather 
than one. Also deserving mention, with alloswitch-1 in a 
trans-amide conformation, S809 does not make a stable H-
bond with the ligand pyridine ring (Figs. 7B and SI 13). This 
is because the plane of alloswitch-1 is changed and no longer 
adopts an optimal orientation for H-bond formation. This 
appears to be because the planar (trans-amide) conformation 
of alloswitch-1 places different constraints on the pyridine 
ring at the bottom of the allosteric pocket. Ultimately 
whether this planarity and lack of protein-ligand H-bonding 
would affect alloswitch-1 functionality is unknown and open 
to speculation. However, this conformation seemingly has 
less in common with the predicted binding-mode of MPEP 
(and mavoglurant) than that of bound alloswitch-1 with a 
cis-amide. Therefore it is possible that the trans-amide 
conformation of alloswitch-1 may not be as functional in 
terms of negative allosterism, although theoretically free to 
bind mGlu5 assuming the receptor adopts a suitable 
conformation.  
 In order to further probe the possibility of a cis-amide 
conformation of alloswitch-1 being the preferred bioactive 
state, a preliminary analysis of force-field potential energies 
was made in the respective MD simulations of the cis-amide 
and trans-amide ligand-mGlu5 complexes (SI Table 3). 
These analyses show the bound cis-amide state of alloswitch-1 
is +3.5 kcal/mol higher than the bound trans-amide state on 
average (this is in relatively good agreement with high-level 
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DFT calculations outside of the receptor, which show the 
cis-amide state is +4.4 kcal/mol higher than the trans-amide 
state; SI Fig. 9). Conversely, protein-ligand interactions with 
the cis-amide state are -3.6 kcal/mol lower than with the 
trans-amide state on average (however it should be noted 
that these are not strict free-energy of binding calculations 
and may over-emphasise protein-ligand interaction energies). 
Taken together, these calculations suggest that although  
the cis-amide state of alloswitch-1 is energetically less 
favourable, more favourable interactions with the protein 
may effectively cancel out this penalty. Thus, both amide 
conformations of alloswitch-1, cis and trans, may be equally 
feasible in energetic terms inside the allosteric pocket of 
mGlu5.  
 
Fig. (6). Two alternative conformations of mGlu5: the original crystal structure (PDB id: 4OO9) (beige) and an alternative state with a wider 
allosteric pocket identified by ROSETTA relaxation (grey). The volume of the allosteric pocket in the original crystal structure is in blue. 
Different sidechain positions between TM6 (left) and TM7 (right) on the extracellular side enable an enlargement of the allosteric pocket, 
primarily through concomitant movement of F788 on TM6 and S805 on TM7. 
 
	  
Fig. (7). A) The best-ranked docking solution of the active isomer of alloswitch-1 (in green) in an alternative ROSETTA conformation of wt 
mGlu5 (in grey). B) After 100 ns of MD simulation “in the dark”. H-bonds are shown as orange lines. For visualisation purposes, the 
backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are included (in the foreground). Regarding 
helix position, TM5 is foreground left, TM7 is foreground right. In the background, TM3 is centre-left and TM2 is centre-right. 
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 As an additional validation along more general lines, the 
prevalence of cis-amides in crystallized organic compounds 
was assessed by screening two structural databases: 
Cambridge Structural Database [45] (CSD; >500,000 small-
molecule compounds in isolation) and Protein Data Bank 
[46] (PDB; 19,209 non-redundant protein-ligand entries). In 
the PDB, 22 non-cyclic ligands (dihedral angle =0° +/-20°) 
out of a total of 4,178 amide-containing ligands were 
identified as having cis-amides (three examples shown in SI 
Fig. 14). In the CSD, 87 compounds were identified as 
containing non-cyclic cis-amides amongst a total of 32,806 
amide-containing compounds (non-powders, non-solvents, 
see SI Fig. 15 for examples). This shows that under normal 
crystallograhic conditions, cis-amides are relatively rare but 
still possible if selective conditions exist. Furthermore, 
ligands with cis-amides may be more common when 
complexed with proteins, which theoretically could help 
stabilize their relatively higher-energy conformation (~0.5% 
occurrence in PDB compared to ~0.3% occurrence in CSD). 
This adds indirect evidence that mGlu5 could theoretically 
stabilize a cis-amide conformation of alloswitch-1 in the 
allosteric pocket by providing suitable mitigating interactions, 
such as an interaction with N747 on TM5, a residue known to 
influence the functionality of amide-containing NAMs [41]. 	  
 So far we have only considered the behaviour of the 
active isomer of alloswitch-1 but this compound also 
possesses a photoisomerizable azo group (Fig. 1). Under 
normal physiological conditions this group resides in trans 
but can switch to cis under violet light. Photoswitching 
appears to alter the biological activity of alloswitch-1 as its 
NAM activity is lost under violet light but regained when the 
light stimulus is removed or green light is applied [29]. 
However, the structural basis for this physiological effect is not 
clear and many questions remain unanswered. For example, 
can the photoisomerized conformation of alloswitch-1 bind 
mGlu5? Can photoswitching of alloswitch-1 occur inside the 
allosteric pocket if the ligand is already bound in its NAM 
state? If so, what happens to the ligand-receptor complex? 
We set out to answer some of these possibilities by simulating 
mGlu5 with a bound photoswitched (cis-azo) conformation 
of alloswitch-1 using two different computational strategies. 
In the first approach, we determined a likely conformation of 
photoexcited alloswitch-1 independently of the receptor (see 
Methods) and then attempted to dock this conformation into 
mGlu5. We followed this with an MD simulation to assess 
protein-ligand stability in a continued photoexcited state. 
This effectively simulates a photoswitching event occurring 
outside of the pocket followed by binding to the receptor in a 
photoisomerized state. In a second approach, we set out to 
simulate potential photoswitching inside the allosteric pocket 
of mGlu5 with alloswitch-1 already bound in its normal 
NAM functional state i.e. photoswitching during an ongoing 
MD simulation with “application of violet light”. For this 
approach we extended two previous MD simulations of 
alloswitch-1 bound to mGlu5 in cis-amide and trans-amide 
conformations and implemented photoswitching of the azo 
group from trans to cis, followed by 100 ns simulation in the 
photoexcited state (see Methods for details). 	  
 Regarding the first photoswitching approach, an 
optimized conformation of the photoexcited state of 
alloswitch-1 was generated by density functional theory 
(DFT) using Gaussian [42] (independently of the receptor, 
see Methods and SI Fig. 16). These calculations place the 
cis-azo dihedral angle at 12.0°, i.e. partially planar. This 
conformation was docked into the original crystal structure 
of mGlu5 with Autodock-4.2 (see Methods). Although the 
docking score of the top-ranked solution is not as favourable 
as previously docked active (trans-azo) isomers (~7-fold less; 
SI Table 2), the non-active (cis-azo) photoisomer still docks 
respectably in the allosteric site, suggesting binding to the 
receptor is possible. However, all 10 docking solutions are 
unable to position the ligand pyridine ring at the bottom of 
the cavity formed between G624 on TM2, Y659 on TM3 and 
A810 on TM7 (top-ranked solution shown in Fig. 8A). This 
is in contrast to the pyridine rings of the trans-azo state of 
alloswitch-1 and MPEP, respectively, which both fill this 
lower cavity. In addition, the ligand methoxy group of the 
photoexcited state is swivelled towards TM5 and its amide 
group is in trans. During a 100 ns MD simulation with the 
azo group maintained in cis (to simulate a continued 
photoexcited state), the ligand experiences considerable 
positional fluctuation, moving vertically and rocking in the 
allosteric pocket, particularly during the first 10 ns of the 
simulation (Figs. 8C and SI 17). At the same time, the 
allosteric pocket experiences structural disruption. In 
particular, the co-crystallized water molecule [24] at the 
bottom of the allosteric pocket is lost during the simulation 
and not rebound. As such, the water-mediated H-bonding 
network connecting TM3 (Y659), TM6 (T781) and TM7 
(S809) is broken and not re-formed. In addition, W785 on 
TM6 is distorted and pushed outwards into an exaggerated 
conformation, which is not observed in any other previous 
simulation or crystal structure, suggesting this is an 
unfavourable state (Fig. 8B). In an energetic analysis of the 
simulation, the cis-azo photoisomer of alloswitch-1 is +6.8 
kcal/mol higher than the trans-azo isomer (SI Table 3) with 
protein-ligand interactions +2.0 kcal/mol higher than the 
active NAM isomer-mGlu5 complex. Taken together, these 
results indicate the photoexcited protein-ligand complex is 
possible but less energetically stable with concomitant 
destabilizing effects on receptor conformation. 
 In a second approach we set out to investigate alloswitch-1 
photoswitching mid-simulation inside of the allosteric 
pocket, with particular focus on receptor destabilization. In 
two MD simulations, with alloswitch-1 in cis-amide and 
trans-amide conformations respectively, changing the azo 
from trans to cis induces a sudden shift in ligand orientation 
and position, as photoexcited alloswitch-1 moves higher in 
the allosteric pocket (closer to exit), experiencing increased 
rocking and lateral fluctuation (SI Figs. 7 and SI 12). In both 
cases, the middle aromatic ring of alloswitch-1 swivels to 
accommodate the cis-azo conformation within the pocket, 
with the methoxy group changing its position by pointing to 
TM7 rather than TM6 and the cis-azo dihedral angle shifting 
to ~0° (from a theoretical optimal angle of 12°) due to 
tightness in the allosteric pocket. Interestingly, in both cases, 
the same destabilizing effect on the receptor is observed as 
before, in that the water-mediated H-bonding network 
connecting TM3 (Y659), TM6 (T781) and TM7 (S809) is 
broken and not re-formed (Fig. 9) as the co-crystallized 
water [24] is lost from the bottom of the allosteric pocket. A 
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very outward orientation of W785 is again observed (Fig. 9), 
particularly in the trans-amide conformation. 
 According to these simulations, it appears theoretically 
possible for a photoswitched state of alloswitch-1 to bind 
mGlu5 although in a different orientation to the unswitched 
state (conventional NAM mode) as it does not reach as far into 
the allosteric pocket. Furthermore, it appears theoretically 
possible from our simulations, which should be taken with 
caution as preliminary calculations, that photoswitching 
might occur in the allosteric pocket of mGlu5. However, 
tightness of the allosteric pocket means the photoexcited 
conformation may be more strained than would be ideal, 
which perhaps could contribute further to protein-ligand 
instability in the photoswitched state. What is not yet clear is 
whether different transition states in between the trans- and 
cis-azo conformations of alloswitch-1 could also bind 
mGlu5. As the transition pathway of photoswitching is 
potentially complex, theoretically combining elements of 
incremental bond rotation and inversion, it is currently not 
possible to answer this question confidently as molecular 
mechanics is unable to simulate different light energy 
conditions or excited electronic states. More experiments and 
higher-level simulations are necessary to address this 
possibility in terms of transitional kinetics. However, in 
terms of a theoretically “instantaneous” photoswitch without 
transition states (see Methods), both trans- and cis-azo 
conformations appear feasible in terms of receptor binding. 
Regarding the receptor, the presence of a co-crystallized 
water molecule has been suggested to be important for the 
NAM activity of mavoglurant by stabilizing the inactive 
state of mGlu5 [24]. It is therefore interesting to observe that 
simulations of mGlu5 containing two conventional but 
different NAMs: MPEP and unswitched alloswitch-1 both 
bind in a stable fashion and stabilize this water molecule in 
the allosteric pocket whilst also forming an H-bond with 
 
Fig. (8). A) The best-ranked docking solution of photoexcited alloswitch-1 (in violet) in mGlu5 (in beige) “in violet light”. B) After 100 ns 
of MD simulation “in violet light”. C) Pronounced lateral oscillation and rocking of photoexcited alloswitch-1 in the first 10 ns of MD 
simulation (two individual conformations displayed within a combined volume). H-bonds are shown as orange lines. For visualisation 
purposes, the backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are included (in the foreground). 
Regarding helix position, TM5 is foreground left, TM7 is foreground right. In the background, TM3 is centre-left and TM2 is centre-right. 
 
Fig. (9). A) The photoexcited conformation of alloswitch-1 (in violet) in mGlu5 (in beige) after 200 ns of MD (0-100 ns in “dark”, 100-200 
ns photoexcited in “light”). B) The photoexcited conformation of alloswitch-1 (in violet) in an alternative receptor conformation (in grey) 
after 200 ns of MD (0-100 ns in “dark”, 100-200 ns photoexcited in “light”). H-bonds are shown as orange lines. For visualisation purposes, 
the backbone of TM6 is not shown, however the sidechains of residues W785 and T781 on TM6 are included (in the foreground). Regarding 
helix position, TM5 is foreground left, TM7 is foreground right. In the background, TM3 is centre-left and TM2 is centre-right. 
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S809 (like mavoglurant). Conversely, the photoswitched 
isomer of alloswitch-1, which has been experimentally 
proven to not behave as a NAM [29], destablizes this co-
crystallized water molecule and does not form an H-bond 
with S809. Does this mean that the inactive state of mGlu5 is 
therefore also destabilized? Possibly yes, but this is 
speculative. It is currently difficult to say what the exact 
functional behaviour of the photoswitched isomer of 
alloswitch-1 is. Certainly the crystallized receptor state is 
destabilized but there may be other functional “inactive” 
states that do not require a bound water molecule between 
TM3/6/7 in the allosteric pocket. It may also be possible that 
photoexcited alloswitch-1 acts as a SAM with no obvious 
functional effects other than preventing the binding of other 
NAMs. 
 It should be noted that although it appears theoretically 
possible from a computational point of view that 
photoisomerized alloswitch-1 binds the allosteric pocket of 
mGlu5, in reality there are several different pathways of 
binding/unbinding available to the ligand in either of its 
photoisomeric states with the receptor, itself in different 
states (see Fig. 10). This means that the dynamics of 
alloswitch-1 may be complicated indeed, with many factors 
influencing its behaviour. For example, it is possible that 
duration of binding of the photoexcited state (assuming it 
occurs) is insignificant compared to other processes, such as 
conventional ligand unbinding of the bioactive NAM state 
and photoisomerization outside of the pocket. It is also 
possible that re-binding of the photoexcited state might be 
prevented by dynamic interactions with receptor extracellular 
loops that partially obstruct the allosteric pocket [24]. 
Further experimental information combined with additional 
computational simulations are needed to test these 
possibilities and explore the reaction kinetics in more detail.	  
CONCLUSIONS	  
 Alloswitch-1 is an interesting and novel mGlu5 NAM, 
similar to other mGlu5 NAMs in that it possesses three 
aromatic rings connected by two spacer groups. However, 
unlike other mGlu5 NAMs, one of these spacers is a photo-
 
Fig. (10). Pathways of alloswitch-1 (A) binding/unbinding to mGlu5 (R). The receptor displays two states: R (inactive) and R* (active). The 
ligand adopts two photoisomeric states: AT (trans-azo: bioactive state) and AC (cis-azo: inactive photoisomerized state) with addition of light 
energy (+hv). The mathematical model includes the possibility of photosimorerization from trans- to cis-azo both in solution and in the 
receptor allosteric pocket. Selection of trans- and cis-azo alloswitch-1 isomers by the inactive and active receptor states are also included in 
the mathematical formalism (see [47] for discussion on ligand induction and conformational selection functional mechanisms). Obviously, in 
dark or green light conditions the proportion of cis-azo isomer is negligible both in solution and in the receptor. 
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sensitive azo group that photoisomerizes from trans to cis 
and back again under violet and green light, respectively. 
Recent experimental evidence has shown that alloswitch-1 is 
a potent NAM under dark/green light conditions but loses its 
NAM functionality under violet light [29]. Here, we propose 
from a structural point of view that the photoswitch of 
alloswitch-1 alters the ligand’s binding mode, reduces its 
binding affinity and stability, and disrupts receptor 
conformation, particularly with regard to the co-bound water 
molecule in the allosteric pocket that has been suggested as 
important for stabilizing the inactive NAM-bound state [24]. 
Molecular simulations suggest binding of the photoswitched 
isomer of alloswitch-1 is possible, as well as theoretical 
“instantaneous” photoswitching in the allosteric pocket of 
mGlu5 while the ligand is bound, although further 
experimental evidence is required to support this possibility. 
Furthermore, by probing MPEP binding, it appears that 
mavoglurant, MPEP and alloswitch-1 all share a common 
binding-mode by stabilizing a receptor conformation that 
contains a bound water molecule at the bottom of the 
allosteric pocket, connecting residues on TM3, TM6, and 
TM7, and characteristic of the NAM-bound inactive state 
[24]. By simulating photoswitching of alloswitch-1, this 
water-mediated connection is lost in the receptor, which may 
destabilize its inactive state. Finally, alloswitch-1 has the 
theoretical capability of isomerizing its amide group between 
cis and trans conformations. This is interesting because an 
amide group is a characteristic feature of several mGlu5 
NAMs and its presence may provide a necessary means of 
flexibilty for these particular ligands to adopt their functional 
binding states. Simulations suggest a cis-amide conformation 
is energetically equivalent to the trans-amide state because 
more favourable protein-ligand interactions are formed with 
residues known to be functionality important for NAM 
functionality e.g. N747 on TM5 and S809 on TM7 [28]. 
These favourable protein-ligand interactions may compensate 
the higher energy state of the cis-amide and at the same time 
fulfill functionally important mechanisms of receptor 
inactivation. On a more general note, cis configurations are 
an interesting possibility in amide-containing ligands (not 
normally considered by default in docking programs) as 
crystallographic structures suggest they can sometimes be 
responsible for important protein or self interactions. 	  
METHODS	  
Experimental	  
 HEK293 cells were transiently transfected with mGlu5 
receptors by electroporation. Receptors were cotransfected 
with EAAC1, a glutamate transporter, to avoid the influence 
of extracellular glutamate. The receptor activity was 
monitored through measurements of inositol monophosphate 
(IP1) production. IP1 production was determined using the 
IP-One HTRF kit (CisBio Bioassays) according to the 
manufacturer’s recommendations [48]. All points were 
performed in triplicate. Mutant receptors were obtained 
using the Quick-Change strategy (Stratagene, La Jolla, CA, 
USA) and all mutations were verified by sequencing. 
Experimental data were fitted using the Hill equation with 
Prism software (GraphPad, La Jolla, CA, USA). Quisqualate 
and MPEP were purchased from Tocris Bioscience (Bristol, 
UK). Alloswitch-1 was synthesized in the laboratory of A. 
Llebaria following described literature procedures [29]. All 
solutions were prepared just before experiments.	  
Computational	  
Completion of wt TM mGlu5 Structure	  
 The TM mGlu5-lysozyme fusion crystal structure (PDB 
id 4OO9) was completed by first cleaving lysozyme and 
removing solvent and fatty acid molecules from the 
structure, then modelling missing second intracellular and 
extracellular loops (ICL2 and ECL2) with MODELLER [32] 
and converting unnatural amino-acids and thermostabilising 
mutations in the TM domain back to wild-type with 
CHIMERA [33] (C634, C691, E579, N667, I669, G675, T742, 
S753). This was done by selecting the most appropriate best-
fit wt rotamer with highest possible statistical probability. 
Co-crystallized water molecules were maintained in the 
structure and mavoglurant ligand was removed.	  
Docking of NAMs	  
 Coordinates of mGlu5 were extracted from OPM 
database [49], PDB id: 4OO9 [24], reorientated in an implicit 
membrane. Cis and trans optimized conformations of the azo 
and amide groups for alloswitch-1 were respectively obtained 
by Density Functional Theory (DFT) at the B3LYP/6-
31+G(d) level using Gaussian [42]. Coordinates for MPEP 
and mavoglurant were generated with Maestro [50]. Autodock 
4.2 was used with “-B amide” flag to give flexibility to 
ligand amide groups and flag “-U nphs_lps_nonstdres” to 
maintain co-crystallized waters in the receptor structure. 
Grid points were extended to cover total allosteric pocket 
volume. For docking cis-azo alloswitch-1 (photoswitched 
state), full ligand flexibility was ensured except the azo 
dihedral angle, which was maintained at +12° as indicated by 
DFT calculations. The final docking conformation of each 
molecule represents the top-ranked hit identified by 
Autodock based on best docking score (expressed as 
predicted Ki) in the largest docking cluster (out of a total of 
10 alternative docking solutions). Energy minimization 
(1000 steps of steepest descent and 100 steps of conjugate 
gradient) of docked structures was performed with 
CHIMERA [33] and the AMBER-12SB force-field [51] to 
relax final docked structures. 	  
Conformational Sampling of mGlu5	  
 Through structural inspection of the mGlu5 crystal 
structure (PDB id: 4OO9), residue F788 on TM6 was identified 
as influential in determining the conformational shape and 
volume of the allosteric pocket of mGlu5. Therefore an 
alternative conformation of mGlu5 for docking alloswitch-1 
was identified by adjusting the rotameric position of F788 
from inward to outward pointing in the mGlu5 crystal structure 
using CHIMERA [33] (selection of second most probable 
rotamer). This structure was then relaxed with ROSETTA 
[52] (minus ligand) in an implicit membrane, generating up 
to 1000 possible conformations, clustered at 2 Å, and the 
highest scoring conformation in the largest cluster selected 
as the final structure. The co-crystallized water molecule at 
the bottom of the allosteric pocket, as well as F788 
sidechain, were positionally constrained during this process.	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Molecular Dynamics (MD)	  
 All MD simulations were performed with NAMD [53] 
v2.9 on the CESCA Supercomputer using the CHARMM-36 
force-field [54]. Membrane (POPC)/solvent (TIP3P) 
simulation boxes were built with VMD Membrane Builder 
[55], with protein insertion in the membrane performed with 
an inhouse VMD-script. All ligands were parameterized with 
CHARMM General Force Field (CGenFF) [56] using the 
ParamChem webserver (https://cgenff.paramchem.org/). Ions 
were added to neutralize the system and salt was added at a 
concentration of 0.2 M. The system was initially minimized 
and then equilibrated with an 8.0 ns MD run with harmonic 
restraints on the protein progressively relaxed every 2.0 ns 
from 10 kcal mol–1 Å–2 to 0 kcal mol–1 Å–2. MD simulations 
were then run for 100-200 ns (production run) for each 
mGlu5-NAM system. In total, four different simulation 
systems were constructed: TM domain of mGlu5 with (i) 
docked MPEP, (ii) docked alloswitch-1 with cis-amide and 
trans-azo (i.e. “dark” state), (iii) docked alloswitch-1 with 
trans-amide and cis-azo (i.e. photoswitched state) and (iv) an 
alternative conformation of the TM domain of mGlu5 with 
docked alloswitch-1 with trans-amide and trans-azo (i.e. 
alternative “dark” state). In two MD simulations (ii) and (iv), 
after 100 ns, the azo dihedral angle of alloswitch-1 was 
changed from trans to cis (azo dihedral angle of 12° was 
presumed for cis state as calculated with DFT) to simulate 
ligand photoswitching. Dihedral angle change was 
implemented in one complete rotational movement within a 
single MD timestep i.e. 2 fs. We describe this as an 
“instantaneous” photoswitch as no transition state between 
trans- and cis-azo is explored. Both simulations (ii) and  
(iv) were continued for another 100 ns with the ligand in a 
cis-azo state, to simulate as closely as possible sustained 
photoswitching conditions. During this time, the azo dihedral 
angle is free to rotate within its cis angle range (-20° to 
+20°) and within the natural confines of the protein. No 
confines were placed on the amide group of alloswitch-1 in 
either simulation, which is free to rotate within the natural 
confines of the protein.	  
MD Analysis	  
 For each MD simulation, VMD plugin [55] 
“NAMDenergy” was used to calculate average bonded and 
non-bonded energies of the ligand and non-bonded energies 
of protein-ligand interactions. The VMD plugin “RMSD 
Trajectory Tool” was used to calculate RMSD values for 
ligand pyridine ring atoms and protein backbone atoms in 
each simulation. VMD plugin “Hydrogen Bonds” was used 
to analyze the formation/breaking of the protein-ligand H-
bond between S809 sidechain and ligand pyridine ring in 
each simulation.	  
Database Searching	  
 Crystallized non-cyclic cis-amide containing-ligands 
(amide dihedral angle: 0°±20°) were identified in the CSD 
[45] by using the Mogul tool [57] v1.7 and non-cyclic cis-
amide ligands were identified in the PDB [46] by geometric 
matching (with an inhouse script) against representative non-
redundant ligands in PDBeChem [58] using an idealized cis-
amide search fragment (i.e. with 0° amide dihedral angle).	  
Structure Visualisation	  
 Chimera [33] was used to visualise structures, calculate 
H-bonds and generate images. POVME [44] was used to 
calculate the volume of the allosteric pocket in mGlu5 by 
using default parameters where possible (see http://nbcr. 
ucsd.edu/data/sw/hosted/POVME/) with grid points adjusted 
to fully map the allosteric site of mGlu5. 
SUPPORTING INFORMATION 
 The supplementary section contains RMSD and H-bond 
plots with energetic analyses from MD simulations; docking 
scores; examples of cis-amide containing compounds 
identified in the CSD [45] and PDB; Density Functional 
Theory (DFT) calculations, and experimental EC50 values. 
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GPCR = G protein-coupled receptor 
TM = transmembrane 
VFT = Venus flytrap 
mGlu5 = metabotropic glutamate receptor 5 
NAM = negative allosteric modulator 
ECL2 = extracellular loop 2 
ICL2 = intracellular loop 2 
RMSD = root mean square deviation 
ND = not determined. 
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